CD274 and neoplasm: Patients with locally advanced or metastatic NSCLC expressing PD-L1 in at least 1% of tumour cells and without eGFR or ALK alterations were enrolled and randomised to receive Tiragolumab (anti-TIGIT monoclonal antibody) plus Atezolizumab (anti-PD-L1) (n = 67) or Atezolizumab alone (n = 68).